IKT Inhibikase Therapeutics
- 2.1300
- -0.2200-9.36%
- 2.2000
- +0.0700+3.29%
Inhibikase Therapeutics News
Inhibikase Therapeutics Analyst Ratings
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Cuts Target Price to $5
Inhibikase Therapeutics Analyst Ratings
Inhibikase Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress
Inhibikase Therapeutics Analyst Ratings
Inhibikase Therapeutics Analyst Ratings
Inhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standing
Promising Developments and Financial Outlook for Inhibikase Therapeutics Prompt Buy Rating
Inhibikase Therapeutics (IKT) Gets a Hold From JonesTrading
Inhibikase Therapeutics Analyst Ratings
H.C. Wainwright Remains a Buy on Inhibikase Therapeutics (IKT)
H.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics (IKT) Receives a Buy From H.C. Wainwright
H.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
JonesTrading Reaffirms Their Hold Rating on Inhibikase Therapeutics (IKT)
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Blue Water Vaccines, Inc. (BWV)
HC Wainwright & Co. Initiates Coverage On Inhibikase Therapeutics With Buy Rating, Announces Price Target of $5
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Inhibikase Therapeutics (IKT)
Analysis
Price Target
No Data
No Data